The FDA has approved Janssen’s antidepressant nasal spray Spravato, making it the first new type of depression treatment to hit the market in 30 years – although its use will be restricted to ...

according to J&J's pharma unit Janssen. Maintaining remission at 32 weeks was a key secondary endpoint, hit by 55% of the Spravato group and 37% of patients taking quetiapine, with the proportion ...

which is marketed under the brand name Spravato, without having to be on another type of antidepressant, according to a statement from the drug's manufacturer, Janssen Pharmaceuticals, that was ...

Pharmaceutical companies cannot patent generic ketamine for depression, but Janssen, a subsidiary of Johnson & Johnson, patented esketamine, which it named Spravato. The cost of the two drugs ...

Living Local 15 host Jessica Williams is joined by Sean Goddard, a Psychiatric Nurse Practitioner and Owner of Viking Psychiatry, to speak about the recent approval for Spravato as a monotherapy ...

and Janssen’s Spravato, an intrana-sal esketamine, was recently approved for use in combination with antidepressants for TRD. “While oral antidepressants take weeks to start having an effect ...

Spravato (esketamine) has possible interactions with alcohol, some other drugs, and certain supplements. Examples include Adderall and benzodiazepines such as clonazepam (Klonopin). Talk with your ...

Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy for adults with treatment-resistant depression. J&J on Tuesday said the green ...

41,366 people played the daily Crossword recently. Can you solve it faster than others?41,366 people played the daily Crossword recently. Can you solve it faster than others?

Stella Mental Health in Westmont specializes in medication management, Spravato (esketamine) nasal spray, transcranial magnetic stimulation (TMS), ketamine infusion therapy, stellate ganglion ...